Polaris Group

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
68.1 ^TWD	-1.59%		+5.58%	-9.92%

2023	Polaris Group Announces the Appointment of K Evin Wu	CI
2023	Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	CI

Polaris Group Appoints K.C. Tsai as Compensation Committee Member

September 26, 2023 at 05:09 am EDT

Polaris Group board of directors appointing K.C. Tsai as compensation committee member Resume of the new position holder: Chairman of Champion Microelectronic Corp. The term of the Compensation Committee is from September 26, 2023, until the date of the company's Annual General Meeting in 2024.

Latest news about Polaris Group

Polaris Group Announces the Appointment of K Evin Wu	Dec. 21	CI
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	Dec. 21	CI
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	Dec. 20	CI
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	Nov. 29	CI
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	Nov. 16	CI
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Polaris Group announced a financing transaction	23-10-05	CI
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	23-09-26	CI
TDW HK Limited announced that it has received $17 million in funding from Polaris Group	23-09-25	CI
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member	23-08-29	CI
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director	23-08-29	CI
Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Polaris Group Announces Dosing of First Patient in Phase 2 Trial of ADI-PEG 20 with Radiation and TMZ in Patients with GBM	23-08-04	CI
Polaris Group Partners with MatrixCare to Improve MDS Assessment Accuracy for Long-Term Care Communities	23-07-27	CI
Polaris Group Announces MFDS Approves Phase Phase 2 Clinical Protocol Treating GBM with ADI-PEG 20	23-06-27	CI
Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023	23-06-12	CI
Polaris Group Announces Executive Changes Effective June 15, 2023	23-06-12	CI
Polaris Group Announces that TFDA Approves Phase3 Clinical Protocol Treatment HCC with ADI-PEG 20	23-05-30	CI
Polaris Group and Vietnam National Cancer Center Announce the Signing of MOU for Future Collaboration	23-05-29	CI
Polaris Group Submits ADI-PEG 20 to TFDA for INR as Treatment for Hepatocellular Carcinoma	23-05-04	CI
DesigneRx Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Polaris Group	23-04-23	CI
Polaris Group Announces the Submission of Polyaris 2020-001 Phase 2 Trial of ADI-PEG 20 to MFDS	23-04-13	CI
Polaris Group Receives Pre-BLA Meeting Notice from US FDA for ADI-PEG 20	23-02-03	CI
Polaris Group Receives IND Approval from US FDA for the Investigational New Drug of ADI-PEG 20 to Treat Soft Tissue Sarcoma	23-01-21	CI
Polaris Group Announces the Signing of MOU with National Health Research Institutes of Taiwan for Future Research Collaboration	22-12-27	CI

Chart Polaris Group

Duration

Period

More charts

Company Profile

Polaris Group is a Cayman Islands-based biopharmaceutical company, which is engaged in advanced therapies, primarily focusing on metabolic related diseases. The Companyâs drug candidate, Pegargiminase (ADI-PEG 20), is advancing through the biologics license applications (BLA) - enabling stage and clinical development. Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Pegargiminase is designed to disrupt cancer cell metabolism, providing a novel approach to treating a range of cancers heavily influenced by metabolic pathways. The Companyâs product pipeline also includes peptide drugs, such as the Semaglutide-related products.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
POLARIS GROUP	-9.92%	1.55B
IQVIA HOLDINGS INC.	+0.67%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.2B
MEDPACE HOLDINGS, INC.	+29.96%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.76B
UNITED THERAPEUTICS CORPORATION	+16.03%	10.4B
BIO-TECHNE CORPORATION	-4.80%	9.94B

Other Biotechnology & Medical Research